Cardiome Announces the Addition of Two Key Members to its Management Team

Cardiome Pharma Corp. announced that it has expanded its management team with the addition of Mr. Frank Murphy, who will serve as Cardiome's Vice President of Finance, and Dr. David Palling, who will serve as the company's Vice President of Manufacturing and Supply Chain. Their roles are effective immediately. 

Mr. Murphy has nearly 20 years of experience in the pharmaceutical industry, most recently as VP of Finance, IT and Supply Chain at Takeda Canada Inc. Previously, he held various senior roles in finance and supply chain at Nycomed, Altana Pharma, and BYK Canada. Mr. Murphy also has nearly 15 years of experience as head of IT at several hospitals in the Niagara region in Ontario, Canada. Mr. Murphy is a Certified Management Accountant (CMA) and holds honours degrees in Finance and Computer Science from Brock University, as well as an MBA from McMaster University.

"We look forward to Frank's contribution to our commercial organization and the breadth of experience he brings to our team," said Jennifer Archibald, Cardiome's CFO.

Dr. Palling has worked in the Pharmaceutical Industry for 30 years and brings experience in the Preclinical and CMC aspects of Drug Development and management of CDMO's. Prior to joining Cardiome, he was a founder and the Chief Manufacturing Officer at Symbiomix LLC, a late stage clinical development company, where he had responsibility for all CMC activities. His other previous roles include: SVP, Therapeutics at Chromocell Corp, where he primarily focused on the discovery and development of novel agents in the pain and respiratory areas; SVP, Technical Operations at Amicus Therapeutics, where he was responsible for bringing its first three products through IND-enabling studies and into Phase 1 clinical trials; and at J&J and Roche where he has held a number of senior-level positions in drug development and CMC. Dr. Palling holds BSc and PhD degrees in Chemistry from the University of London and carried out Post-Doctoral Research in Biochemistry at Brandeis University in Waltham, MA.

Speaking on the hiring of Dr. Palling, Sheila Grant, Cardiome's COO said, "We are pleased that David will be heading up our manufacturing and supply chain as we continue to expand our product offerings worldwide. His knowledge and experience in manufacturing and pharmaceutical development in senior level roles at both large and small pharma companies will serve us well as we continue to grow from a small company to a larger, commercial player. We also thank Dr. Taryn Boivin for her many years of leading the manufacturing and supply chain efforts of the company and leaving us with such a strong team. We wish her well in her future endeavours."

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies that will improve the quality of life and health of patients suffering from disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS^® (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT^® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD^® and ESMOCARD LYO^® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf of their partner AOP Orphan Pharma in select European markets. Cardiome has also licensed: XYDALBA™ (dalbavancin hydrochloride), a second generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations and Canada from Allergan; and TREVYENT^®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension for Europe, the Middle East and for Canadian markets from SteadyMed Therapeutics.

For more information, please visit www.cardiome.com.